Metsera chasing best-in-class profile with amylin program

The first Phase I data for Metsera’s amylin program validated investor interest Monday, helping the company continue to shine as one of the best performing biotech stocks in what’s been an otherwise dismal year.

Amylin is one of the hottest new targets in obesity, with both Abbvie Inc. (NYSE:ABBV) and Roche (SIX:ROG; OTCQX:RHHBY) spending big in partnerships this year to gain access to clinical candidates. The growing interest stems from amylin’s potential to be combined with incretins such as GLP-1R agonists to produce greater weight loss, as well as the target’s potential to be used as monotherapy to drive higher quality weight loss that can be lean mass-sparing while lowering the severity of GI side effects...